BeiGene, Ltd. (6160.HK)
HKD 105.9
(-1.4%)
HKD 105.9
(-1.4%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.28 Billion USD | 157.05% |
| 2022 | 1.27 Billion USD | 29.04% |
| 2021 | 990.87 Million USD | 64.86% |
| 2020 | 601.02 Million USD | 54.28% |
| 2019 | 389.57 Million USD | 98.48% |
| 2018 | 196.27 Million USD | 212.29% |
| 2017 | 62.85 Million USD | 212.74% |
| 2016 | 20.09 Million USD | 174.89% |
| 2015 | 7.31 Million USD | 5.5% |
| 2014 | 6.93 Million USD | 120.49% |
| 2013 | 3.14 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 910.17 Million USD | 1.14% |
| 2024 Q1 | 888.06 Million USD | -2.66% |
| 2023 Q4 | 912.37 Million USD | 11.41% |
| 2023 Q1 | 328.68 Million USD | -0.15% |
| 2023 Q3 | 818.96 Million USD | 107.22% |
| 2023 Q2 | 395.22 Million USD | 20.24% |
| 2023 FY | 3.28 Billion USD | 157.05% |
| 2022 Q4 | 329.17 Million USD | 1.89% |
| 2022 FY | 1.27 Billion USD | 29.04% |
| 2022 Q3 | 323.07 Million USD | -2.57% |
| 2022 Q2 | 331.59 Million USD | 12.49% |
| 2022 Q1 | 294.76 Million USD | -3.89% |
| 2021 Q1 | 182.29 Million USD | -12.53% |
| 2021 Q2 | 232.47 Million USD | 27.53% |
| 2021 Q3 | 269.41 Million USD | 15.89% |
| 2021 FY | 990.87 Million USD | 64.86% |
| 2021 Q4 | 306.68 Million USD | 13.83% |
| 2020 FY | 601.02 Million USD | 54.28% |
| 2020 Q2 | 124.23 Million USD | 15.72% |
| 2020 Q3 | 161.02 Million USD | 29.61% |
| 2020 Q4 | 208.39 Million USD | 29.42% |
| 2020 Q1 | 107.36 Million USD | -25.28% |
| 2019 Q1 | 57.97 Million USD | -20.39% |
| 2019 FY | 389.57 Million USD | 98.48% |
| 2019 Q2 | 82.58 Million USD | 42.44% |
| 2019 Q3 | 105.33 Million USD | 27.55% |
| 2019 Q4 | 143.68 Million USD | 36.41% |
| 2018 FY | 196.27 Million USD | 212.29% |
| 2018 Q4 | 72.82 Million USD | 48.59% |
| 2018 Q3 | 49 Million USD | 8.07% |
| 2018 Q2 | 45.34 Million USD | 55.82% |
| 2018 Q1 | 29.1 Million USD | 5.44% |
| 2017 Q2 | 10.77 Million USD | 22.9% |
| 2017 Q1 | 8.76 Million USD | 5.18% |
| 2017 FY | 62.85 Million USD | 212.74% |
| 2017 Q4 | 27.6 Million USD | 75.76% |
| 2017 Q3 | 15.7 Million USD | 45.72% |
| 2016 FY | 20.09 Million USD | 174.89% |
| 2016 Q2 | 3.9 Million USD | 24.57% |
| 2016 Q4 | 8.33 Million USD | 76.56% |
| 2016 Q3 | 4.72 Million USD | 20.95% |
| 2016 Q1 | 3.13 Million USD | 6.24% |
| 2015 Q4 | 2.95 Million USD | 45.97% |
| 2015 FY | 7.31 Million USD | 5.5% |
| 2015 Q1 | 1.13 Million USD | -30.38% |
| 2015 Q2 | 1.2 Million USD | 6.71% |
| 2015 Q3 | 2.02 Million USD | 67.3% |
| 2014 Q2 | 594 Thousand USD | 0.0% |
| 2014 Q3 | 3.8 Million USD | 540.07% |
| 2014 Q1 | 594 Thousand USD | 0.0% |
| 2014 FY | 6.93 Million USD | 120.49% |
| 2014 Q4 | 1.62 Million USD | -57.23% |
| 2013 FY | 3.14 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 325.05 Million HKD | -911.104% |
| CK Life Sciences Int'l., (Holdings) Inc. | 739.25 Million HKD | -344.582% |